Cozen O'Connor | USA | 18 Jan 2024
A coalition of 12 AGs wrote a letter to the Drug Enforcement Administration (DEA) in support of federal efforts to evaluate and reschedule cannabis…
Mintz | USA | 24 Oct 2023
On October 10, 2023, the Drug Enforcement Administration (DEA) published another temporary rule extending the COVID-era telemedicine flexibilities…
Lexology PRO | Canada, France, Global, etc. | 15 Sep 2023
The OPDA warns AstraZeneca over misleading claims, Italy reclassifies CBD products, and the UK Government defers new rules that will require packaging manufacturers to cover recycling costs – plus other key updates.
McGuireWoods LLP | USA | 6 Jul 2023
Over the past few years, the conversation surrounding recreational and medical use of psilocybin has shifted due to growing evidence of its…
Sheppard Mullin Richter & Hampton LLP | USA | 12 May 2023
This week, the Drug Enforcement Administration (“DEA”), in conjunction with the Substance Abuse and Mental Health Services Administration (“SAMHSA”)…
Riker Danzig LLP | USA | 11 May 2023
After loosening the in-person requirements in prescribing controlled substances (“CDs”) during COVID-19, the Drug Enforcement Administration ("DEA")…
Benesch Friedlander Coplan & Aronoff LLP | USA | 4 May 2023
Earlier this year in late February, the Drug Enforcement Administration (DEA) announced proposed rules attempting to change the rules for…
Bradley Arant Boult Cummings LLP | USA | 14 Mar 2023
On March 1, 2023, the Drug Enforcement Administration (DEA) released the proposed rule, "Telemedicine Prescribing of Controlled Substances When the…
Bradley Arant Boult Cummings LLP | USA | 9 Mar 2023
Last week, we wrote about the Drug Enforcement Administration’s (DEA) February 13, 2023 response letter stating that delta-8 THCO and delta-9 THCO -…
McDermott Will & Emery | USA | 28 Feb 2023
On February 24, 2023, the US Drug Enforcement Administration (DEA) issued two proposed rules (the Telemedicine Controlled Substance Proposed Rule and…